Atty Dkt No. 6200-0013
Serial No. 09/716,029

C2 9 ~~52.~~ (Amended) The pharmaceutical composition of claim 10 ~~47~~, wherein said nitrogen-containing solvent is selected from the group consisting of N-methyl 2-pyrrolidone, N-ethyl 2-pyrrolidone and mixtures thereof.

C3 10 ~~51.~~ (Twice Amended) A method for treating a patient suffering from a lipid disorder, comprising administering to the patient a therapeutically effective amount of the composition of claim ~~54~~ 1.

C4 D 1 ~~54.~~ (Amended) A pharmaceutical composition for oral administration of fenofibrate, comprising:

a) a therapeutically effective amount of fenofibrate; and

b) an effective solubilizing amount of a solubilizer selected from the group consisting of: a trialkyl citrate; a lactone; a combination of a trialkyl citrate and a lactone; a combination of a vitamin E substance and at least one of a trialkyl citrate and a lactone, ~~and a nitrogen-containing solvent,~~ and a combination of a nitrogen-containing solvent and at least one of a trialkyl citrate and a lactone.

C5 15 ~~59.~~ (Amended) The pharmaceutical composition of claim 1 ~~54~~, in a semi-solid form.

16 17 ~~61.~~ (Amended) The pharmaceutical dosage form of claim ~~60~~ 16, comprising a unit dosage form.

17 18 ~~62.~~ (Amended) The pharmaceutical dosage form of claim ~~61~~ 17, comprising about 40 mg to about 250 mg fenofibrate.

C6 18 19 ~~63.~~ (Amended) The pharmaceutical dosage form of claim ~~62~~ 18, comprising about 67 mg to about 200 mg fenofibrate.

1 20 ~~67.~~ (Amended) The pharmaceutical composition of claim ~~54~~ 1, wherein the fenofibrate has not been micronized.

C7 1 23 ~~68.~~ (Amended) The pharmaceutical composition of claim ~~54~~ 1, wherein the fenofibrate has been micronized in the absence of a solid surfactant.

43

C

Atty Dkt No. 6200-0013
Serial No. 09/716,029

Cont'l D 44 69. (Amended) The pharmaceutical composition of claim 54, wherein the solubilizer comprises a combination of a vitamin E substance and at least one of a trialkyl citrate, a lactone ~~and a nitrogen containing solvent~~.

C7 25 70. (Amended) The pharmaceutical composition of claim 69, wherein the vitamin E substance is selected from the group consisting of tocopherols, tocopherol derivatives with organic acids, tocotrienols, individual enantiomers thereof, and mixtures of any of the foregoing.

26 71. (Amended) The pharmaceutical composition of claim 70, wherein the vitamin E substance is selected from the group consisting of alpha-tocopherol, alpha-tocopheryl acetate, alpha-tocopheryl acid succinate, alpha-tocopheryl polyethylene glycol 1000 succinate, individual enantiomers thereof, and mixtures of any of the foregoing.

27 92. (Amended) The method of claim 51, wherein the lipid disorder is an above-normal level of cholesterol.

28 93. (Amended) The method of claim 51, wherein the lipid disorder is an above-normal triglyceride level.

C8 29 94. (Amended) The method of claim 51, wherein the lipid disorder is a below-normal level of high density lipoproteins.

Also add new claims 95-98, as set forth in Appendix A. The new claims are also reproduced below.

30 95. (New) The pharmaceutical composition of claim 71, wherein said vitamin E substance is alpha-tocopheryl polyethylene glycol 1000 succinate or an individual enantiomer thereof.

C9 31 96. (New) The pharmaceutical composition of claim 71, wherein said vitamin E substance comprises a mixture of alpha-tocopheryl polyethylene glycol 1000 succinate and alpha-tocopherol.

32 97. (New) The pharmaceutical composition of claim 71, selected from the group consisting of d-alpha-tocopherol, d,l-alpha-tocopherol, d-alpha-tocopheryl acetate, and d,l-alpha-tocopheryl acetate.

44

C